Ginger McMillian
Family · Montgomery, TXNPI 1306237664
Payments from drug & device makers
Across 128 payments — averaging $17.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$354
- Takeda Pharmaceuticals U.S.A., Inc.$262
- AbbVie$246
- Novo Nordisk$172
- Lilly USA, LLC$120
- Pfizer$106
- plus $948 from 28 others
What the payments were for
- Food & beverage$2,10996%
- Education$994%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 19 | $354 |
| Takeda Pharmaceuticals U.S.A., Inc. | 17 | $262 |
| AbbVie(2 entities) | 18 | $246 |
| Novo Nordisk | 10 | $172 |
| Lilly USA, LLC | 8 | $120 |
| Pfizer | 4 | $106 |
| Astellas Pharma US Inc | 1 | $99 |
| Galderma Laboratories, L.p. | 5 | $96 |
| Otsuka America Pharmaceutical, Inc. | 6 | $95 |
| GSK | 4 | $69 |
| Novartis | 3 | $59 |
| Acella Pharmaceuticals, LLC | 2 | $36 |
| Amgen | 2 | $34 |
| Currax Pharmaceuticals LLC | 2 | $32 |
| Genentech USA, Inc. | 2 | $32 |
| Exact Sciences | 2 | $32 |
| Antares Pharma, Inc. | 2 | $32 |
| Mayne Pharma Commercial LLC | 1 | $31 |
| Sanofi-aventis U.S. LLC | 2 | $30 |
| Bayer | 2 | $28 |
| Idorsia Pharmaceuticals US Inc | 1 | $24 |
| Biohaven Pharmaceuticals, Inc. | 1 | $22 |
| Abbott | 1 | $21 |
| Bausch Health US, LLC | 1 | $21 |
| Clarus Therapeutics Inc. | 3 | $20 |
| Dexcom, Inc. | 1 | $18 |
| Cranial Technologies, Inc | 1 | $17 |
| Sunovion Pharmaceuticals Inc. | 1 | $16 |
| Axsome Therapeutics, Inc. | 1 | $15 |
| Boehringer Ingelheim | 1 | $15 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| Johnson & Johnson | 1 | $15 |
| Halozyme Inc | 1 | $14 |
| Eisai Inc. | 1 | $14 |
How this compares
$2,208 in reported general payments places this provider in the 80th percentile of 15,456 family providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 35 | $37,444 |
| OzempicSemaglutide | 18 | $23,374 |
| TrulicityDulaglutide | 15 | $21,767 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 14 | $18,804 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 12 | $18,097 |
| JanuviaSitagliptin Phosphate | 11 | $12,327 |
| Breo ElliptaFluticasone/Vilanterol | 14 | $9,718 |
| MyrbetriqMirabegron | 14 | $8,763 |
| Dexlansoprazole DrDexlansoprazole | 13 | $5,571 |
| Liothyronine Sodium | 39 | $1,840 |
| Metoprolol Succinate | 75 | $1,419 |
| Levothyroxine Sodium | 155 | $1,374 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 40 | $1,267 |
| ProgesteroneProgesterone, Micronized | 24 | $1,252 |
| Nebivolol Hcl | 15 | $1,120 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $120 | $59,21150 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $69 | $28,52228 claims |
| Novo NordiskOzempic | $172 | $23,37418 claims |
| Boehringer IngelheimCombivent Respimat | $15 | $18,09712 claims |
| Astellas Pharma US IncMyrbetriq | $99 | $8,76314 claims |
| AbbVieSynthroid, Armour Thyroid | $246 | $1,63726 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 15,456 family providers in Texas.
Other family in Montgomery
- Lashonda CraneHouston$3.4M
- David WeirDallas$959K
- Luba YammineHouston$479K
- Robin BeachHouston$428K
- Nirupama JeromeAustin$418K
- April LopezMcAllen$417K
- Linda MercadoHouston$211K
- Sarah AguilarHouston$199K
- Sie ThomasDallas$197K
- Anna CastroSan Antonio$184K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.